VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
VBL Therapeutics (Nasdaq: VBLT) will host a conference call on November 16, 2020, at 8:30 am ET to report third-quarter financial results and provide a corporate update. The company focuses on developing first-in-class treatments for cancer, with lead candidate Ofranergene obadenovec (VB-111) targeting solid tumors, currently in a Phase 3 trial for platinum-resistant ovarian cancer. VBL's technologies include gene-therapy and antibody platforms.
- Lead product candidate Ofranergene obadenovec in Phase 3 trial for platinum-resistant ovarian cancer.
- Well-tolerated in >300 cancer patients with demonstrated activity in earlier trials.
- None.
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, November 16, 2020 at 8:30am Eastern Time to report third quarter ended September 30, 2020 financial results and to provide a corporate update.
| Monday, November 16 @ 8:30amET | ||
| From the US: | 877-407-9208 | |
| International: | 201-493-6784 | |
| Israel: | 1 809 406 247 | |
| Conference ID: | 13711944 | |
| Webcast: | https://edge.media-server.com/mmc/p/5wkkzaat | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
FAQ
What are the financial results announced by VBL Therapeutics for Q3 2020?
What is the focus of VBL Therapeutics?
When is VBL Therapeutics' conference call scheduled?
What is the lead product candidate from VBL Therapeutics?
